BACKGROUND: Synovial sarcoma (SS) is a malignant soft tissue sarcoma with a poor prognosis because of late local recurrence and distant metastases. To our knowledge, no studies have minimum follow-up of 10 years that evaluate long-term outcomes for survivors. PATIENTS AND METHODS: Data on 62 patients who had been treated for SS from 1968 to 1999 were studied retrospectively in a multicenter study. Mean follow-up of living patients was 17.2 years and of dead patients 7.7 years. RESULTS: Mean age at diagnosis was 35.4 years (range 6-82 years). Overall survival was 38.7%. The 5-year survival was 74.2%; 10-year survival was 61.2%; and 15-year survival was 46.5%. Fifteen patients (24%) died of disease after 10 years of follow-up. Local recurrence occurred after a mean of 3.6 years (range 0.5-14.9 years) and metastases at a mean of 5.7 years (range 0.5-16.3 years). Only four patients were treated technically correctly with a planned biopsy followed by a wide resection or amputation. Factors associated with significantly worse prognosis included larger tumor size, metastases at the time of diagnosis, high-grade histology, trunk-related disease, and lack of wide resection as primary surgical treatment. CONCLUSIONS: In SS, metastases develop late with high mortality. Patients with SS should be followed for >10 years.
BACKGROUND: Synovial sarcoma (SS) is a malignant soft tissue sarcoma with a poor prognosis because of late local recurrence and distant metastases. To our knowledge, no studies have minimum follow-up of 10 years that evaluate long-term outcomes for survivors. PATIENTS AND METHODS: Data on 62 patients who had been treated for SS from 1968 to 1999 were studied retrospectively in a multicenter study. Mean follow-up of living patients was 17.2 years and of dead patients 7.7 years. RESULTS: Mean age at diagnosis was 35.4 years (range 6-82 years). Overall survival was 38.7%. The 5-year survival was 74.2%; 10-year survival was 61.2%; and 15-year survival was 46.5%. Fifteen patients (24%) died of disease after 10 years of follow-up. Local recurrence occurred after a mean of 3.6 years (range 0.5-14.9 years) and metastases at a mean of 5.7 years (range 0.5-16.3 years). Only four patients were treated technically correctly with a planned biopsy followed by a wide resection or amputation. Factors associated with significantly worse prognosis included larger tumor size, metastases at the time of diagnosis, high-grade histology, trunk-related disease, and lack of wide resection as primary surgical treatment. CONCLUSIONS: In SS, metastases develop late with high mortality. Patients with SS should be followed for >10 years.
Authors: Bernhard M Speth; Andreas H Krieg; Andre Kaelin; G Ulrich Exner; Louis Guillou; Arthur von Hochstetter; Gernot Jundt; Fritz Hefti Journal: J Child Orthop Date: 2011-08-11 Impact factor: 1.548
Authors: Theodore S Nowicki; Ryan Akiyama; Rong Rong Huang; I Peter Shintaku; Xiaoyan Wang; Paul C Tumeh; Arun Singh; Bartosz Chmielowski; Christopher Denny; Noah Federman; Antoni Ribas Journal: Cancer Immunol Res Date: 2016-12-30 Impact factor: 11.151
Authors: Jared J Barrott; Ju-Fen Zhu; Kyllie Smith-Fry; Asia M Susko; Dakota Nollner; Lance D Burrell; Amir Pozner; Mario R Capecchi; Jeffrey T Yap; Lisa A Cannon-Albright; Xingming Deng; Kevin B Jones Journal: Mol Cancer Res Date: 2017-08-29 Impact factor: 5.852
Authors: Bridget Charbonneau; Rachel Isaksson Vogel; J Carlos Manivel; Anthony Rizzardi; Stephen C Schmechel; Simona Ognjanovic; Subbaya Subramanian; David Largaespada; Brenda Weigel Journal: Hum Pathol Date: 2013-05-10 Impact factor: 3.466